Lacosamide (Vimpat)

Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.

About Lacosamide

What it is

Lacosamide is an anticonvulsant that enhances the slow inactivation of sodium channels in nerve cells, which steadies overactive firing without blocking normal signalling. It is used for focal seizures, alone or with other medicines, and for generalised tonic-clonic seizures, as tablets, syrup or drip. It is sold as Vimpat.

How genes come into it

Lacosamide is cleared partly unchanged by the kidneys and partly by liver enzymes including CYP2C19. Studies have found modestly higher levels in CYP2C19 poor metabolizers, and have looked at the transporter ABCC2 for levels and response. The effects are small, and there is no CPIC or DPWG guideline.

What research found

Every published finding on gene variants and Lacosamide. Upload your DNA file to see which of these rows apply to you.

Metabolism (6 findings)

Studies of how quickly the body processes this medication.

ABCC2 rs2273697: Genotype GG is associated with increased concentrations of lacosamide in children with Epilepsy as compared to genotypes AA + AG.

ABCC2 rs717620: Allele T is associated with decreased exposure to lacosamide in children with Epilepsy as compared to allele C.

ABCC2 rs717620: Genotype CC is associated with increased concentrations of lacosamide in children with Epilepsy as compared to genotypes CT + TT.

CYP2C19 CYP2C19 normal metabolizer: CYP2C19 normal metabolizer is associated with decreased exposure to lacosamide in children with Epilepsy as compared to CYP2C19 intermediate metabolizer and poor metabolizer.

Response (3 findings)

Studies of how well it worked in people carrying a variant.

ABCC2 rs2273697: Allele A is associated with increased resistance to lacosamide in children with Epilepsy as compared to allele G.

ABCC2 rs717620: Allele T is associated with increased resistance to lacosamide in children with Epilepsy as compared to allele C.

CYP2C19 rs4244285: Genotypes AA + AG is associated with increased clinical benefit to lacosamide in children with Epilepsy as compared to genotype GG.

Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.

Related Drugs

More drugs from the same category

Antiepileptics (class) (Anticonvulsants)

Cerebyx (Anticonvulsants)

Depakote (Anticonvulsants)

Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.

Back to Medications

Content updated September 2026.

ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.

Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026

Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com